@article{8d28824fbcfa463b9b7b10ef3757f06a,
title = "Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America",
abstract = "The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investment by major pharmaceutical companies in antimicrobial research and development. Although smaller companies are stepping forward to address this gap, their success is uncertain. The IDSA proposed legislative and other federal solutions to this emerging public health problem in its July 2004 policy report {"}Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews.{"} At this time, the legislative response cannot be predicted. To emphasize further the urgency of the problem for the benefit of legislators and policy makers and to capture the ongoing frustration our clinician colleagues experience in their frequent return to an inadequate medicine cabinet, the AATF has prepared this review to highlight pathogens that are frequently resistant to licensed antimicrobials and for which few, if any, potentially effective drugs are identifiable in the late-stage development pipeline.",
author = "Talbot, {George H.} and John Bradley and Edwards, {John E.} and David Gilbert and Michael Scheid and Bartlett, {John G.}",
note = "Funding Information: Potential conflicts of interest. G.H.T. currently serves as an advisor for Actelion, Advancis, Array, Cerexa, Cubist, Cumbre, ICOS, Mpex, Os-cient, Replidyne, Sanofi-Aventis, Serenex, Ther-avance, ViroPharma, and Wyeth. J.B. provides his stipend and research support to Children{\textquoteright}s Hospital San Diego and affiliates for general Infectious Diseases Division support; serves on the advisory boards of Actelion, Astra-Zeneca, Elan, and Johnson & Johnson; and receives research support from Astra-Zeneca, Elan, GlaxoSmithKline, Merck, and Novartis. J.E.E. serves on the scientific advisory boards of Pfizer, Merck, Vicuron, and Gilead; has participated in educational programs regarding fungal infections funded by Pfizer, Merck, and As-tellas; has received research laboratory support from Pfizer, Merck, and Gilead; and has participated in the Bristol-Myers Squibb Freedom to Discovery research program. D.G. serves on the speakers{\textquoteright} bureau of Abbott Laboratories, Bayer, GlaxoSmithKline, Lilly, Merck, Pfizer, Roche, Sch-ering-Plough, and Wyeth. M.S. serves on advisory boards of Pfizer, Cubist, and GlaxoSmithKline and serves on speakers{\textquoteright} bureaus of these same companies, plus those of Schering-Plough and Bristol-Myers Squibb. J.G.B. serves on the HIV advisory boards for Bristol-Myers Squibb, Abbott Laboratories, and GlaxoSmithKline.",
year = "2006",
month = mar,
day = "1",
doi = "10.1086/499819",
language = "English (US)",
volume = "42",
pages = "657--668",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",
}